Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 10:58 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 11,325 matching trials from the live ClinicalTrials.gov search.
Filters: Cleveland, Ohio Clear all
Completed No phase listed Observational

NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer

NCT02103634
View directory record Official record
Conditions
Malignant Neoplasm of Breast TNM Staging Distant Metastasis (M), Untreated Bone Metastases
Interventions
NaF PET/MRI, NaF PET/CT, FDG PET/CT
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Nov 2, 2026, 10:58 AM EST
Terminated Phase 3 Interventional Results available

12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

NCT02586909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101 35 mg tablets
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 86 Years
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Rancho Mirage, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Nov 2, 2026, 10:58 AM EST
Completed Phase 1 Interventional

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

NCT04861987
View directory record Official record
Conditions
Advanced Cancer, Refractory Cancer, Tumor Gastric
Interventions
PCS6422 and capecitabine
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Omaha, Nebraska • New Brunswick, New Jersey • Santa Fe, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Nov 2, 2026, 10:58 AM EST
Active, not recruiting No phase listed Observational

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass

NCT06566716
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
CleoDX ovarian cancer test
Diagnostic Test
Lead sponsor
Cleo Diagnostics Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Chandler, Arizona • Jacksonville, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 2, 2026, 10:58 AM EST
Completed Phase 3 Interventional Results available

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

NCT00877006
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
bendamustine, rituximab, vincristine, prednisone, cyclophosphamide, doxorubicin
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
79
States / cities
Tucson, Arizona • Little Rock, Arkansas • Corona, California + 70 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Nov 2, 2026, 10:58 AM EST
Completed Phase 2 Interventional

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00080106
View directory record Official record
Conditions
HIV Infections
Interventions
MRK Ad5 HIV-1 gag vaccine, Vaccine placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 2, 2026, 10:58 AM EST
Completed Not applicable Interventional

A Pilot Study of Allogeneic Lymphocyte Transfer in HIV Infection

NCT00000852
View directory record Official record
Conditions
HIV Infections
Interventions
Allogeneic lymphocyte transfer
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 10:58 AM EST
Completed Not applicable Interventional

Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

NCT00004855
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Abacavir sulfate, Nevirapine, Lamivudine, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
23
States / cities
Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 2, 2026, 10:58 AM EST
Terminated Phase 2 Interventional Results available

TRACER RGD-K5 Carotid Plaque Imaging Study

NCT01968226
View directory record Official record
Conditions
Carotid Artery Disease, Carotid Stenosis
Interventions
[F-18] RDG-K5
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Nov 2, 2026, 10:58 AM EST
Recruiting Phase 2 Interventional

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

NCT05838521
View directory record Official record
Conditions
Cervical Cancer
Interventions
Sacituzumab govitecan
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 2, 2026, 10:58 AM EST
Terminated Phase 3 Interventional

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

NCT00366704
View directory record Official record
Conditions
Schizophrenia
Interventions
bifeprunox, risperidone
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
66
States / cities
Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Nov 2, 2026, 10:58 AM EST
Completed No phase listed Observational Results available

Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study

NCT01178333
View directory record Official record
Conditions
Heparin Induced Thrombocytopenia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
21
States / cities
Iowa City, Iowa • New Orleans, Louisiana • Baltimore, Maryland + 12 more
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Nov 2, 2026, 10:58 AM EST
Completed Phase 3 Interventional

Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

NCT01082549
View directory record Official record
Conditions
Squamous Cell Lung Cancer
Interventions
gemcitabine/carboplatin, gemcitabine/carboplatin plus Iniparib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Nov 2, 2026, 10:58 AM EST
Terminated Phase 2 Interventional

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

NCT05588609
View directory record Official record
Conditions
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
Interventions
Afatinib Oral Tablet, Enzalutamide Pill, Abiraterone acetate tablets, MCLA-128
Drug · Biological
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Whittier, California • Lake Mary, Florida • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 2, 2026, 10:58 AM EST
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

NCT02569398
View directory record Official record
Conditions
Asymptomatic Amyloid-positive
Interventions
Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
557 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 2, 2026, 10:58 AM EST
Terminated Not applicable Interventional

T-ABA Group Based Early Intervention For Parents of Children With ASD

NCT02202421
View directory record Official record
Conditions
Autism
Interventions
Targeted Applied Behavior Analysis (T-ABA)
Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
24 Months to 71 Months
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Nov 2, 2026, 10:58 AM EST
Terminated Not applicable Interventional Results available

Targeted Breast Milk Fortification for Very Low Birth Weight Infants in the NICU

NCT04025021
View directory record Official record
Conditions
Human Milk, Neonate, Breast Milk
Interventions
Targeted Fortification, The Miris Human Milk Analyzer
Dietary Supplement · Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
Up to 6 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Nov 2, 2026, 10:58 AM EST
Completed Phase 3 Interventional Results available

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

NCT00507416
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Melphalan, Prednisone, Thalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
234
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Nov 2, 2026, 10:58 AM EST
Completed No phase listed Observational

Donors After Cardiac Death: Validating Identification Criteria

NCT00177606
View directory record Official record
Conditions
Withdrawing Treatment
Interventions
withdrawal of life sustaining treatments
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
Up to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Cincinnati, Ohio • Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Nov 2, 2026, 10:58 AM EST
Completed No phase listed Observational

Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test

NCT04635384
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Not listed
Lead sponsor
CareDx
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
10
States / cities
Brisbane, California • Duarte, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 10:58 AM EST
Not yet recruiting Not applicable Interventional

WATER IV PCa (AS Sub-study)

NCT07650448
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
Aquablation Therapy, Active Surveillance
Device · Other
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
45 Years and older · Male only
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
26
States / cities
Chandler, Arizona • Los Angeles, California • Murrieta, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 2, 2026, 10:58 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Self-Monitoring OCT

NCT07584798
View directory record Official record
Conditions
Obtaining OCT (Optical Coherence Tomography) Images
Interventions
Self-administered OCT imaging system, Technician-acquired OCT imaging
Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Nov 2, 2026, 10:58 AM EST
Completed Phase 2 Interventional Results available

Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery

NCT02526498
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive, Invasive Breast Carcinoma, Progesterone Receptor Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer
Interventions
Accelerated Partial Breast Irradiation, High-Dose Rate Brachytherapy, Questionnaire Administration
Radiation · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
45 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Royal Oak, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Nov 2, 2026, 10:58 AM EST
Completed No phase listed Observational

Organ Donor Tissue Oxygen Saturation as a Predictor of Number of Organs to Transplant Per Donor

NCT01819116
View directory record Official record
Conditions
Brain Death
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
15 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Nov 2, 2026, 10:58 AM EST